- Home
- » Tags
- » Bendamustine
Top View
- Is Bendamustine-Rituximab a Reasonable Treatment in Selected Older Patients with Diffuse Large B Cell Lymphoma? Results from a Multicentre, Retrospective Study
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents Lorenzo M
- Evolution of Nitrogen-Based Alkylating Anticancer Agents
- Phase III Randomized Study of Bendamustine Compared with Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic
- Australian Public Assessment Report for Bendamustine Hydrochloride
- Rituximab Plus Bendamustine Or Chlorambucil for Chronic Lymphocytic Leukemia: Primary Analysis of the Randomized, Open-Label MABLE Study
- Patients with Marginal Zone Dural Lymphoma Successfully Treated with Rituximab and Bendamustine: a Report of Two Cases
- Bendamustine
- Cost-Effectiveness Analysis of Arsenic Trioxide for the Treatment of Patients with Acute Promyelocytic Leukemia in the US
- Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide
- Levact® I.V. (Bendamustine Hcl)
- MEDICAL REVIEW(S) Clinical Review, Division of Drug Oncology Products Virginia Kwitkowski NDA 22-303 /Bendamustine (Treanda)
- Emetogenic Potential of Antineoplastic Agents
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
- Peripheral T-Cell Lymphoma
- (PDF) Download
- Understanding My Treatment with BENDEKA®
- Pharmacist Involvement in the Management of Adverse Effects
- Omacetaxine: a Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Latest News in Blood Cancer Research Highlights from the 2012 Annual Meeting of the American Society of Hematology CONNECT BOOKLET SERIES ®
- Clinical Response and Pharmacokinetics of Bendamustine As a Component of Salvage R-B(O)AD Therapy for the Treatment of Primary C
- Bendamustine, Etoposide and Dexamethasone to Mobilize Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
- Bendamustine-Rituximab
- NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Follicular Lymphoma (Grade 1–2) (Part 1 of 3)
- Pixantrone, Etoposide, Bendamustine, Rituximab (P[R]EBEN) As an Effective Salvage Regimen for Relapsed/Refractory Aggressive
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- Bendamustine Pharmaceutical Compositions for Lyophilisation
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Standard Oncology Criteria Policy Number: Pending
- Download Master-Thesis
- Bendamustine: Treanda®; Bendeka®; Belrapzo™
- Bendamustine-Etoposide-Cytarabine-Melphalan
- BENDEKA (Bendamustine Hydrochloride) Injection Is an Alkylating Drug Occurred
- 1 Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab
- Reference ID: 4263446 17 PATIENT COUNSELING INFORMATION *Sections Or Subsections Omitted from the Full Prescribing Information Are Not Listed
- Clinical Policy: Bendamustine (Bendeka, Treanda)
- Full Text (PDF)
- February 5, 2019 O & M Halyard, Inc. Angela Bunn Director of Regulatory Affairs 5405 Windward Parkway Alpharetta, Georgia 30
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Bendamustine in B-Cell Malignancies: the New 46-Year-Old Kid on the Block Varsha Gandhi1,2 and Jan A
- (Cyclophosphamide, Bendamustine and Etoposide) Pre-Autotransplant Conditioning in Persons with Lymphoma
- Hazardous Drug List
- Managing Pharmacotherapy in People Living with HIV And
- How to Manage Mantle Cell Lymphoma